Literature DB >> 16647248

Candidaemia in Europe: epidemiology and resistance.

Anna Maria Tortorano1, Christopher Kibbler, Javier Peman, Hannelore Bernhardt, Lena Klingspor, Renee Grillot.   

Abstract

Despite the widespread use of antifungals for prophylaxis, Candida bloodstream infection (BSI) remains the most frequent life-threatening fungal disease. From an analysis of multi-institutional surveys of Candida BSIs performed in Europe, including the large prospective survey by the European Confederation of Medical Mycology (2089 episodes from seven countries), a limited role of species with decreased susceptibility to azoles in causing BSIs and a low proportion of antifungal resistance was evident. Large prospective epidemiological surveys using common databases are needed to monitor trends in incidence and changes in species distribution, to identify new at-risk patients and to evaluate the impact of the introduction into the market of new antifungal agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647248     DOI: 10.1016/j.ijantimicag.2006.01.002

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  97 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 2.  Will resistance in fungi emerge on a scale similar to that seen in bacteria?

Authors:  H Hof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

Review 3.  Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Authors:  Ercole Concia; Anna Maria Azzini; Michela Conti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

4.  Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.

Authors:  Maria Siopi; Aikaterini Tarpatzi; Eleni Kalogeropoulou; Sofia Damianidou; Alexandra Vasilakopoulou; Sophia Vourli; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 5.  Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.

Authors:  Matteo Bassetti; Franco Aversa; Filippo Ballerini; Fabio Benedetti; Alessandro Busca; Nicola Cascavilla; Ercole Concia; Andrea Tendas; Francesco Di Raimondo; Patrizio Mazza; Anna Maria Nosari; Giuseppe Rossi
Journal:  Clin Drug Investig       Date:  2011-11-01       Impact factor: 2.859

6.  Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.

Authors:  D L Horn; L Ostrosky-Zeichner; M I Morris; A J Ullmann; C Wu; D N Buell; L L Kovanda; O A Cornely
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12-15       Impact factor: 3.267

Review 7.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

8.  A first Portuguese epidemiological survey of fungaemia in a university hospital.

Authors:  S Costa-de-Oliveira; C Pina-Vaz; D Mendonça; A Gonçalves Rodrigues
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

9.  Molecular epidemiology of Candida albicans and its closely related yeasts Candida dubliniensis and Candida africana.

Authors:  Orazio Romeo; Giuseppe Criseo
Journal:  J Clin Microbiol       Date:  2008-11-05       Impact factor: 5.948

10.  Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.

Authors:  Bertrand F Dupont; Olivier Lortholary; Luis Ostrosky-Zeichner; Flavie Stucker; Vijay Yeldandi
Journal:  Crit Care       Date:  2009-10-05       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.